Abstracts tagged "metabolomics and rheumatic disease"

Abstract Number: 1241 • 2015 ACR/ARHP Annual Meeting
Identification and Validation of Diagnostic and Activity Urinary Metabolomic Biomarkers in Immune-Mediated Inflammatory Diseases
Arnald Alonso¹, Jesús Tornero², Antonio Fernandez-Nebro³, Juan D. Cañete⁴, Eugeni Domènech⁵, Javier P. Gisbert⁶, Carlos Ferrándiz⁵, Eduardo Fonseca⁷, Valle García⁸, Francisco Blanco⁷, Jesus Rodriguez⁹, Jordi Gratacós¹⁰, Patricia E. Carreira¹¹, Antonio Julià¹, Raül Tortosa¹, Maria López-Lasanta¹², Xavier Correig¹³ and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ³Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, ⁴Unitat d’Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pí i Sunyer, Barcelona, Spain, ⁵Hospital Universitari Germans Trias I Pujol, Badalona, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Complejo Hospitalario Juan Canalejo, A Coruña, Spain, ⁸Hospital Universitario Reina Sofía, Córdoba, Spain, ⁹Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ¹⁰Hospital Parc Taulí, Sabadell, Spain, ¹¹Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹²Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ¹³CIBERDEM, Metabolomics Platform, Reus, Spain
Background/Purpose: The recent advances in metabolomics have allowed the study of the regulatory processes linked to metabolism. The comprehensive analysis of the metabolome in biological samples…
Abstract Number: 2097 • 2014 ACR/ARHP Annual Meeting
Identification of Diagnostic and Activity Metabolomic Urine Biomarkers in Six Immune-Mediated Inflammatory Diseases
Arnald Alonso¹, Jesús Tornero², Antonio Fernandez Nebro³, Juan D. Cañete⁴, Eugeni Domènech⁵, Javier P. Gisbert⁶, Carlos Ferrándiz⁵, Eduardo Fonseca⁷, Valle García⁸, Francisco Blanco⁷, Jesus Rodriguez⁹, Jordi Gratacós¹⁰, Patricia Carreira¹¹, Toni Julia¹, Raül Tortosa¹, María América López-Lasanta¹, Xavier Correig¹² and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Hospital Universitario Guadalajara, Guadalajara, Spain, ³Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ⁴Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Hospital Universitari Germans Trias I Pujol, Badalona, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Complejo Hospitalario Juan Canalejo, A Coruña, Spain, ⁸Hospital Universitario Reina Sofía, Córdoba, Spain, ⁹Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ¹⁰Hospital Parc Taulí, Sabadell, Spain, ¹¹Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, ¹²CIBERDEM, Metabolomics Platform, Reus, Spain
Background/Purpose: Metabolomics is an emergent research field within the omics sciences aimed at characterizing the metabolome in complex biological samples. It provides a powerful approach…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].